Targeting with scFv: Immune modulation by complement receptor specific constructs

Journal of Molecular Recognition

Volumn 16, Issue 5, 2003, Pages 318-323

  Molnár, Eszter ^a   Prechl, József ^a   Isaák, Andrea ^a   Erdei, Anna ^a  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

Antigen; Complement; CR; scFv; Targeting

Indexed keywords

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG DELIVERY SYSTEMS; EPITOPES; FORECASTING; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; ORTHOMYXOVIRIDAE; RECEPTORS, COMPLEMENT; RECEPTORS, COMPLEMENT 3B;

EID: 0141942107     PISSN: 09523499     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmr.642     Document Type: Conference Paper

References (35)

1. Alvarez-Vallina L, Hawkins RE. 1996. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur. J. Immunol. 26: 2304-2309.
2. Arvieux J, Yssel H, Colomb MG. 1988. Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of human T-cell clones. Immunology 65: 229-235.
3. Baiu DC, Prechl J, Tchorbanov A, Molina HD, Erdei A, Sulica A, Capel PJ, Hazenbos WL. 1999. Modulation of the humoral immune response by antibody-mediated antigen targeting to complement receptors and Fc receptors. J. Immunol. 162: 3125-3130.
4. Boackle SA, Holers VM, Karp DR. 1997. CD21 augments antigen presentation in immune individuals. Eur. J. Immunol. 27: 122-129.
5. Carayanniotis G, Skea DL, Luscher MA, Barber BH. 1991. Adjuvant-independent immunization by immunotargeting antigens to MHC and non-MHC determinants in vivo. Mol. Immunol. 28: 261-267.
6. Carroll MC, Fischer MB. 1997. Complement and the Immune response. Curr. Opin. Immunol. 9: 64-69.
7. Casten LA, Pierce SK. 1988. Receptor-mediated B cell antigen processing. Increased antigenicity of a globular protein covalently coupled to antibodies specific for B cell surface structures. 140: 404-440.
8. Cherukuri A, Cheng PC, Sohn HW, Pierce SK. 2001. The CD19/CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts. Immunity 14: 169-179.
9. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271: 348-350.
10. Eshhar Z, Waks T, Gross G, Schindler DG. 1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90: 720-724.
11. Fearon DT, Carter RH. 1995. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. A. Rev. Immunol. 13: 127-149.
12. Fingeroth JD, Benedict MA, Levy DN, Strominger JL. 1989. Identification of murine complement receptor type 2. Proc. Natl Acad. Sci. USA 86: 242-246.
13. Gustavsson S, Hjulstrom S, Liu T, Heyman B. 1994. CD23/IgE-mediated regulation of the specific antibody response in vivo. J. Immunol. 152: 4793-4800.
14. Gustavsson S, Kinoshita T, Heyman B. 1995. Antibodies to murine complement receptor 1 and 2 can inhibit the antibody response in vivo without inhibiting T helper cell induction. J. Immunol. 154: 6524-6528.
15. Hebell T, Ahearn JM, Fearon DT. 1991. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 254: 102-105.
16. Kinoshita T, Takeda J, Hong K, Kozono H, Sakai H, Inoue K. 1988. Monoclonal antibodies to mouse complement receptor type 1 CR1. Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative. J. Immunol. 140: 3066-3072.
17. Kinoshita T, Thyphronitis G, Tsokos GC, Finkelman FD, Hong K, Sakai H, Inoue K. 1990. Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor. Int. Immunol. 2: 651-659.
18. Liu C, Goldstein J, Graziano RF, He J, O'Shea JK, Deo Y, Guyre PM. 1996a. FcgammaRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes. J. Clin. Invest. 98: 2001-2007.
19. Liu C, Gosselin EJ, Guyre PM. 1996b. Fc gamma RII on human B cells can mediate enhanced antigen presentation. Cell Immunol. 167: 188-194.
20. Manca F. 1992. Galactose receptors and presentation of HIV envelope glycoprotein to specific human T cells. J. Immunol. 148: 2278-2282.
21. Mitsuda S, Nakagawa T, Osada T, Shimamoto T, Nakazato H, Ikai A. 1993. A receptor mediated delivery of an HIV-1 derived peptide vaccine. Biochem. Biophys. Res. Commun. 194: 1155-1160.
22. Mjaaland S, Fossum S. 1990. Modulation of immune responses with monoclonal antibodies. I. Effects on regional lymph node morphology and on anti-hapten responses to haptenized monoclonal antibodies. Eur. J. Immunol. 20: 1457-1461.
23. Molina H, Holers VM, Li B, Fung Y, Mariathasan S, Goellner J, Strauss-Schoenberger J, Karr RW, Chaplin DD. 1996. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl Acad. Sci. USA 93: 3357-3361.
24. Pramoonjago P, Takeda J, Kim YU, Inoue K, Kinoshita T. 1993. Ligand specificities of mouse complement receptor types 1 CR1 and 2 CR2 purified from spleen cells. Int. Immunol. 5: 337-343.
25. Prechl J, Tchorbanov A, Horvath A, Baiu DC, Hazenbos W, Rajnavolgyi E, Kurucz I, Capel PJ, Erdei A. 1999. Targeting of influenza epitopes to murine CR1/CR2 using single-chain antibodies. Immunopharmacology 42: 159-165.
26. Prechl J, Baiu DC, Horvath A, Erdei A. 2002. Modeling the presentation of C3d-coated antigen by B lymphocytes: enhancement by CR1/2-BCR co-ligation is selective for the coligating antigen. Int. Immunol. 14: 241-247.
27. Rajnavolgyi E, Nagy Z, Kurucz I, Gogolak P, Toth GK, Varadi G, Penke B, Tigyi Z, Hollosi M, Gergely J. 1994. T cell recognition of the posttranslationally cleaved intersubunit region of influenza virus hemagglutinin. Mol. Immunol. 31: 1403-1414.
28. Squire CM, Studer EJ, Lees A, Finkelman FD, Conrad DH. 1994. Antigen presentation is enhanced by targeting antigen to the Fc epsilon RII by antigen-anti-Fc epsilon RII conjugates. J. Immunol. 152: 4388-4396.
29. Tazzari PL, Polito L, Bolognesi A, Pistillo MP, Capanni P, Palmisano GL, Lemoli RM, Curti A, Biancone L, Camussi G, Conte R, Ferrara GB, Stirpe F. 2001. Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: in vitro results and in vivo effects in an acute rejection model. J. Immunol. 167: 4222-4229.
30. Thornton BP, Vetvicka V, Ross GD. 1994. Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. J. Immunol. 152: 1727-1737.
31. Thyphronitis G, Kinoshita T, lnoue K, Schweinle JE, Tsokos GC, Metcalf ES, Finkelman FD, Balow JE. 1991. Modulation of mouse complement receptors 1 and 2 suppresses antibody responses in vivo. J. Immunol. 147: 224-230.
32. Villiers MB, Villiers CL, Laharie AM, Marche PN. 1999. Amplification of the antibody response by C3b complexed to antigen through an ester link. J. Immunol. 162: 3647-3652.
33. Wiersma EJ, Kinoshita T, Heyman B. 1991. Inhibition of immunological memory and T-independent humoral responses by monoclonal antibodies specific for murine complement receptors. Eur. J. Immunol. 21: 2501-2506.
34. Wu X, Jiang N, Fang YF, Xu C, Mao D, Singh J, Fu YX, Molina H. 2000. Impaired affinity maturation in Cr2-/- mice is rescued by adjuvants without improvement in germinal center development. J. Immunol. 165: 3119-3127.
35. Yoshida S, Kobayashi T, Matsuoka H, Seki C, Gosnell WL, Chang SP, Ishii A. 2002. T cell activation and cytokine production via a bispecific single-chain antibody fragment targeted to blood-stage malaria parasites. Blood. 101: 2300-2306.